Treatment Advances in HR+/HER2- Metastatic Breast Cancer

Nadia Harbeck, MD, PhD; Alessandra Gennari, MD


October 18, 2022

Hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) breast cancer is the most common breast cancer subtype. Once the disease has metastasized, it is not curable. Nevertheless, significant improvements in overall survival in HR+/HER2- metastatic breast cancer have been achieved in recent clinical trials.

In this panel ReCAP, oncologists Dr Nadia Harbeck and Dr Alessandra Gennari ​discuss recent updates presented at ESMO 2022 and ASCO 2022 that inform treatment decisions, including data on the CDK4/6 inhibitors abemaciclib, ribociclib, and palbociclib.

They close their commentary by examining antibody-drug conjugates as a second-line treatment option for patients with HR+/HER2- breast cancer. Specifically, they discuss overall survival improvements provided by trastuzumab deruxtecan and sacituzumab govitecan compared with chemotherapy alone.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.